Back to Journals » International Journal of General Medicine » Volume 1

A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia

Authors Amy S Chappell, Laurence A Bradley, Curtis Wiltse, Michael J Detke, Deborah N D’Souza, Michael Spaeth

Published 9 December 2008 Volume 2008:1 Pages 91—102

DOI https://doi.org/10.2147/IJGM.S3979

Review by Single-blind

Peer reviewer comments 2

Amy S Chappell1, Laurence A Bradley2, Curtis Wiltse1, Michael J Detke1,3,4, Deborah N D’Souza1, Michael Spaeth5

1Lilly Research Laboratories, Indianapolis, IN, USA; 2University of Alabama at Birmingham, Birmingham, Alabama, USA; 3Indiana University School of Medicine, Indianapolis, IN, USA; 4Harvard Medical School, Boston, MA, USA; 5Practice for Internal Medicine/Rheumatology, Graefelfing, Germany

Objective: Assess the efficacy of duloxetine 60/120 mg (N = 162) once daily compared with placebo (N = 168) in the treatment of patients with fibromyalgia, during six months of treatment.

Methods: This was a phase-III, randomized, double-blind, placebo-controlled, parallel-group study assessing the efficacy and safety of duloxetine.

Results: There were no significant differences between treatment groups on the co-primary efficacy outcome measures, change in the Brief Pain Inventory (BPI) average pain severity from baseline to endpoint (P = 0.053) and the Patient’s Global Impressions of Improvement (PGI-I) at endpoint (P = 0.073). Duloxetine-treated patients improved significantly more than placebo-treated patients on the Fibromyalgia Impact Questionnaire pain score, BPI least pain score and average interference score, Clinical Global Impressions of Severity scale, area under the curve of pain relief, Multidimensional Fatigue Inventory mental fatigue dimension, Beck Depression Inventory-II total score, and 36-item Short Form Health Survey mental component summary and mental health score. Nausea was the most common treatment-emergent adverse event in the duloxetine group. Overall discontinuation rates were similar between groups.

Conclusions: Although duloxetine 60/120 mg/day failed to demonstrate significant improvement over placebo on the co-primary outcome measures, in this supportive study, duloxetine demonstrated significant improvement compared with placebo on numerous secondary measures.

Keywords: fibromyalgia, duloxetine, placebo, double-blind, trial, pain

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Prescribing tests must have curriculum support

Lemon TI, Shah RD

Advances in Medical Education and Practice 2013, 4:91-93

Published Date: 7 May 2013

Retraction

Cárdenas WH, Mamani JB, Sibov TT, Caous CA, Amaro E Jr, Gamarra LF

International Journal of Nanomedicine 2012, 7:5107-5108

Published Date: 21 September 2012

Sensitivity and specificity of median nerve ultrasonography in diagnosis of carpal tunnel syndrome

Yazdchi M, Tarzemani MK, Mikaeili H, Ayromlu H, Ebadi H

International Journal of General Medicine 2012, 5:99-103

Published Date: 26 January 2012

Argatroban in the management of heparin-induced thrombocytopenia

Luciano Babuin, Vittorio Pengo

Vascular Health and Risk Management 2010, 6:813-819

Published Date: 1 September 2010

Release profile and stability evaluation of optimized chitosan/alginate nanoparticles as EGFR antisense vector

Ebrahim Azizi, Alireza Namazi, Ismaeil Haririan, et al

International Journal of Nanomedicine 2010, 5:455-461

Published Date: 29 June 2010

A ‘brain tumor’ in an intravenous drug abuser

Kathir Yoganathan

International Journal of General Medicine 2009, 2:73-75

Published Date: 22 April 2009

An online conserved SSR discovery through cross-species comparison

Tun-Wen Pai, Chien-Ming Chen, Meng-Chang Hsiao, Ronshan Cheng, Wen-Shyong Tzou, Chin-Hua Hu

Advances and Applications in Bioinformatics and Chemistry 2009, 2:23-35

Published Date: 8 February 2009

Antiglaucoma drugs for achieving monovision after laser in situ keratomileusis

Kazutaka Kamiya, Kimiya Shimizu

Clinical Ophthalmology 2009, 3:211-213

Published Date: 8 February 2009

Relationship of anthropometric indicators with blood pressure levels and the risk of hypertension in Nigerian adults

Rufus A Adedoyin, Chidozie E Mbada, Luqman A Bisiriyu, Rasaaq A Adebayo, Michael O Balogun, Anthony O Akintomide

International Journal of General Medicine 2008, 1:33-40

Published Date: 31 August 2008